Trial
NCT03697824
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
Merck Sharp & Dohme LLC
Condition
Neoplasms
Intervention
GSK3377794
Why stopped
Internal decision, study will be replaced with a larger monotherapy trial
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-29